Jacobs Levy Equity Management’s MacroGenics MGNX Stock Holding History

Jacobs Levy Equity Management’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.63M	Buy	1,002,274 +561,131	+127%	+$2.12M	0.02%	451
2026 Q1	$1.27M	Sell	441,143 -459,914	-51%	-$981K	0.01%	666
2025 Q4	$1.45M	Buy	901,057 +85,192	+10%	+$134K	0.01%	632
2025 Q3	$1.37M	Sell	815,865 -188,933	-19%	-$306K	0.01%	661
2025 Q2	$1.22M	Buy	1,004,798 +339,447	+51%	+$492K	﹤0.01%	721
2025 Q1	$845K	Buy	665,351 +99,447	+18%	+$260K	﹤0.01%	843
2024 Q4	$1.84M	Sell	565,904 -424	-0.1%	-$1.53K	0.01%	605
2024 Q3	$1.86M	Buy	566,328 +147,438	+35%	+$574K	0.01%	619
2024 Q2	$1.78M	Buy	418,890 +270,872	+183%	+$2.64M	0.01%	624
2024 Q1	$2.18M	Buy	148,018 +33,039	+29%	+$499K	0.01%	580
2023 Q4	$1.11M	Sell	114,979 -284,505	-71%	-$1.97M	0.01%	698
2023 Q3	$1.86M	Sell	399,484 -5,502	-1%	-$27.4K	0.01%	570
2023 Q2	$2.17M	Buy	404,986 +100,864	+33%	+$622K	0.01%	547
2023 Q1	$2.18M	Buy	304,122 +248,386	+446%	+$1.5M	0.01%	557
2022 Q4	$374K	Buy	+55,736	New	+$306K	﹤0.01%	834
2022 Q3	–	Sell	-71,224	Closed	-$210K	–	1107
2022 Q2	$210K	Sell	71,224 -97,000	-58%	-$510K	﹤0.01%	955
2022 Q1	$1.48M	Buy	+168,224	New	+$1.86M	0.01%	683
2020 Q4	–	Sell	-18,484	Closed	-$466K	–	1064
2020 Q3	$466K	Sell	18,484 -192,152	-91%	-$5.25M	﹤0.01%	807
2020 Q2	$5.88M	Sell	210,636 -11,809	-5%	-$205K	0.06%	305
2020 Q1	$1.29M	Buy	+222,445	New	+$2.02M	0.02%	572
2019 Q2	–	Sell	-34,300	Closed	-$617K	–	995
2019 Q1	$617K	Sell	34,300 -108,566	-76%	-$1.88M	0.01%	749
2018 Q4	$1.81M	Buy	142,866 +5,000	+4%	+$83.9K	0.03%	476
2018 Q3	$2.96M	Sell	137,866 -11,304	-8%	-$241K	0.04%	430
2018 Q2	$3.08M	Buy	149,170 +28,273	+23%	+$637K	0.05%	409
2018 Q1	$3.04M	Sell	120,897 -27,139	-18%	-$659K	0.05%	387
2017 Q4	$2.81M	Buy	148,036 +74,485	+101%	+$1.39M	0.05%	392
2017 Q3	$1.36M	Buy	73,551 +54,161	+279%	+$938K	0.03%	524
2017 Q2	$340K	Sell	19,390 -86,060	-82%	-$1.64M	0.01%	755
2017 Q1	$1.96M	Buy	105,450 +84,250	+397%	+$1.63M	0.04%	430
2016 Q4	$433K	Buy	+21,200	New	+$534K	0.01%	705
2016 Q3	–	Sell	-53,817	Closed	-$1.45M	–	1087
2016 Q2	$1.45M	Sell	53,817 -29,140	-35%	-$657K	0.03%	489
2016 Q1	$1.55M	Buy	+82,957	New	+$1.58M	0.03%	467

Other funds holding MGNX

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Jacobs Levy Equity Management's MGNX Position: Q2 2026 in Review

Jacobs Levy Equity Management increased its MacroGenics (MGNX) stake by 127% in Q2 2026, buying an estimated $2.12M and bringing the position to 1,002,274 shares worth $4.63M. The position accounts for 0.02% of the portfolio, ranked #451.

Jacobs Levy Equity Management first reported a position in MGNX in Q1 2016 and has held it in 32 quarters since. The position peaked at $5.88M in Q2 2020. 122 funds tracked by Wall St. Rank hold MGNX as of Q2 2026.

Jacobs Levy Equity Management held 1,002,274 shares of MacroGenics worth $4.63M as of Q2 2026.
Jacobs Levy Equity Management bought 561,131 MacroGenics shares in Q2 2026, an estimated $2.12M.
MacroGenics made up 0.02% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #451 holding.
Jacobs Levy Equity Management first reported a position in MacroGenics in Q1 2016 and has held it in 32 quarters since.
Jacobs Levy Equity Management's MacroGenics position peaked at $5.88M in Q2 2020.
122 funds tracked by Wall St. Rank held MacroGenics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.